MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
Cocrystal Pharma Operating Expenses 2011-2026 | COCP
Annual Operating Expenses Cocrystal Pharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.02 M | 17.9 M | 18.6 M | 38.8 M | 14.2 M | 11.6 M | 8.87 M | 62.9 M | 8.26 M | 106 M | 54 M | 5.81 M | 3.3 M | 9.86 M | 7.85 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 106 M | 3.3 M | 25.1 M |
Quarterly Operating Expenses Cocrystal Pharma
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.09 M | 2.11 M | 2.34 M | - | 5.04 M | 5.45 M | 4.16 M | - | 4.44 M | 4.34 M | 5.11 M | - | 5.69 M | 24.4 M | 4.2 M | - | 3.95 M | 3.83 M | 2.74 M | - | 3.2 M | 4 M | 2.42 M | - | 2.3 M | 2.14 M | 2.2 M | - | 2.42 M | 2.13 M | 2.07 M | 1.83 M | 2.11 M | 2.11 M | 3.12 M | 94.4 M | 1.89 M | 4.2 M | 5.33 M | 44.4 M | 3.61 M | 3.84 M | 2.2 M | - | 1.22 M | 1.39 M | 1.53 M | - | 1 M | 1.03 M | 1.06 M | - | 1.57 M | 1.77 M | 2.04 M | - | 4.3 M | 1.34 M | 1.2 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 94.4 M | 1 M | 6.07 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K |  USA |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
16.7 M | $ 3.88 | 3.89 % | $ 9.34 B |  Australia |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
1.13 B | $ 323.46 | -2.98 % | $ 42.4 B | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
Burford Capital Limited
BUR
|
106 M | $ 4.7 | -0.63 % | $ 766 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Cabaletta Bio
CABA
|
172 M | $ 3.55 | 4.26 % | $ 357 M | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Aligos Therapeutics
ALGS
|
90.2 M | $ 8.1 | 9.16 % | $ 80.1 M | USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 21.91 | 1.04 % | $ 1.02 B | USA |
 |
CymaBay Therapeutics
CBAY
|
133 M | - | - | $ 3.45 B | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 101.31 | 1.85 % | $ 27.2 B | Germany |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 3.07 | -3.15 % | $ 5.05 M | Israel |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Galectin Therapeutics
GALT
|
20.1 M | $ 2.3 | -10.35 % | $ 147 M | USA |
 |
ContraFect Corporation
CFRX
|
64.6 M | - | -5.16 % | $ 5.39 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
173 M | $ 1.39 | -10.32 % | $ 357 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Grifols, S.A.
GRFS
|
1.64 B | $ 8.57 | -1.44 % | $ 6.83 B |  Spain |
 |
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.21 | -0.71 % | $ 450 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
137 M | $ 23.86 | -2.93 % | $ 3.04 B | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.54 | 3.02 % | $ 410 M | Britain |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Checkpoint Therapeutics
CKPT
|
56.2 M | - | - | $ 169 M | USA |
 |
Incyte Corporation
INCY
|
1.62 B | $ 95.06 | -2.11 % | $ 18.6 B | USA |
 |
Caladrius Biosciences
CLBS
|
23.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Clearside Biomedical
CLSD
|
33.1 M | - | - | $ 25.3 M | USA |